Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582071 | 0.89 | FYN (0.39) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5582148 | 0.89 | CSNK2A1 (0.44) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5581770 | 0.88 | ADORA1 (0.40) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5581820 | 0.88 | ADORA1 (0.43) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5581799 | 0.86 | FYN (0.41) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5581729 | 0.86 | FYN (0.52) | FYNJAK2JAK1 | |
| SCHEMBL5582247 | 0.85 | ADORA1 (0.39) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5581976 | 0.85 | PDE4B (0.39) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5582028 | 0.84 | SCN9A (0.40) | CSNK2A2CSNK2BCSNK2A1SCN9AADORA1 | |
| SCHEMBL5581995 | 0.84 | CSNK2A1 (0.50) | CSNK2A2CSNK2BCSNK2A1ADORA1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | CSNK2A2 467/4885CSNK2B 662/4885CSNK2A1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.